Andrew Gorman - Access Bio B Board

All Insiders . Korea . 
Stock . Access Bio . Stakeholders . Insider . Andrew Gorman
950130 Stock  KRW 4,995  75.00  1.48%   

Insider

Andrew Gorman is B Board of Access Bio
Phone732 873 4040
Webhttp://www.accessbiodiagnostics.net

Andrew Gorman Latest Insider Activity

Tracking and analyzing the buying and selling activities of Andrew Gorman against Access Bio stock is an integral part of due diligence when investing in Access Bio. Andrew Gorman insider activity provides valuable insight into whether Access Bio is net buyers or sellers over its current business cycle. Note, Access Bio insiders must abide by specific rules, including filing SEC forms every time they buy or sell Access Bio'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
 
Andrew Gorman over six months ago
Disposition of 766 shares by Andrew Gorman of Brady at 73.53 subject to Rule 16b-3
 
Andrew Gorman over six months ago
Disposition of 300 shares by Andrew Gorman of Brady at 42.01 subject to Rule 16b-3

Access Bio Management Efficiency

The company has return on total asset (ROA) of 0.3467 % which means that it generated a profit of $0.3467 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 108.0209 %, meaning that it generated $108.0209 on every $100 dollars invested by stockholders. Access Bio's management efficiency ratios could be used to measure how well Access Bio manages its routine affairs as well as how well it operates its assets and liabilities.
Access Bio has accumulated 10.13 M in total debt with debt to equity ratio (D/E) of 0.13, which may suggest the company is not taking enough advantage from borrowing. Access Bio has a current ratio of 16.15, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Access Bio until it has trouble settling it off, either with new capital or with free cash flow. So, Access Bio's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Access Bio sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Access to invest in growth at high rates of return. When we think about Access Bio's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

SungGeun JungEBEST Investment Securities
60
JiHo YounEBEST Investment Securities
56
JongHo LeeEBEST Investment Securities
52
KyungGeun ParkEBEST Investment Securities
60
Hyunjoo LeeEBEST Investment Securities
58
MaengGeun SongEBEST Investment Securities
58
Yooho JungEBEST Investment Securities
55
Joonhyo LeeSBI Investment KOREA
N/A
So EiichiroSBI Investment KOREA
48
HyungKi KimSBI Investment KOREA
N/A
DaeJin KimSBI Investment KOREA
64
Seokhee ParkSBI Investment KOREA
N/A
SukJin YooSBI Investment KOREA
59
Won KimEBEST Investment Securities
63
JongYeol JungEBEST Investment Securities
60
ChangRo LeeSBI Investment KOREA
58
YoungJin KimEBEST Investment Securities
43
Kwanho ShinSBI Investment KOREA
N/A
MiJung LeeSBI Investment KOREA
N/A
Kim HyukSBI Investment KOREA
N/A
Access Bio, Inc. researches, develops, and manufactures in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products. Access Bio (950130) is traded on KOSDAQ in Korea and employs 69 people.

Management Performance

Return On Equity108.02
Return On Asset0.35

Access Bio Leadership Team

Elected by the shareholders, the Access Bio's board of directors comprises two types of representatives: Access Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Access. The board's role is to monitor Access Bio's management team and ensure that shareholders' interests are well served. Access Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Access Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
Andrew Gorman, B Board
Terry Kim, Chief Africa
Philip CPA, Treasurer Board
John Kim, Managing Partner
N MD, Clinical Board
YoungHo Choi, CEO Pres
Janet Strong, DODG Board

Access Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Access Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity108.02
Return On Asset0.35
Profit Margin0.40 %
Operating Margin0.55 %
Current Valuation1.03 T
Shares Outstanding26.79 M
Shares Owned By Insiders25.25 %
Shares Owned By Institutions0.08 %
Price To Earning149.71 X
Price To Sales1.44 X

Pair Trading with Access Bio

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Access Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Access Bio will appreciate offsetting losses from the drop in the long position's value.

Moving together with Access Stock

  0.89205470 HumasisPairCorr

Moving against Access Stock

  0.38005490 POSCO HoldingsPairCorr
The ability to find closely correlated positions to Access Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Access Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Access Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Access Bio to buy it.
The correlation of Access Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Access Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Access Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Access Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Access Stock

Access Bio financial ratios help investors to determine whether Access Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Access with respect to the benefits of owning Access Bio security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY